Antimicrobial Stewardship

February 14, 2017

Rebecca Margevicius, Pharm.D., BCPS Clinical Pharmacy Specialist Antimicrobial Stewardship rmargevicius@swgeneral.com



Objectives

- Recognize the urgent need for antimicrobial stewardship
- List the benefits of having an antimicrobial stewardship program
- Provide examples of effective Antimicrobial Stewardship in a Community Hospital



Why Stewardship?

 Inappropr Optimize Patient Safety – Adverse and Outcomes - Clostridit Limit inappropriate and - Antimicro Excessive Antibiotic Use Mortality **Reduce Drug Resistance** - Cost **Ensure Cost** Limited ar pment **Effectiveness**

Clin Infect Dis (2008) 47 (6): 735-743



Why Stewardship? Cont'd

In recognition of the urgent need to improve antibiotic use in hospitals and the benefits of antibiotic stewardship programs, in 2014 CDC recommended that all acute care hospitals implement Antibiotic Stewardship Programs

Get Better Here.

Southwest General

University Hospitals

MMWR (2014) 63

Not Just an Inpatient Issue...





Data source: IMS Health Xponent 2014.

*Fleming-Dutra, K., et al. (2016). 'Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011." JAMA: the Journal of the American Medical Association 315(17): 1864–1873.



Southwest General

- Business plan for Antimicrobial Stewardship Pharmacist drafted July 2014
 - Implemented January 2015
- Key members
 - ID Physician (0.25 FTE)
 - ID Pharmacist (1 FTE)
 - Infection Prevention Nurse
 - Microbiology
 - Quality



Daily Stewardship

- Daily Chart Review
 - House wide review
 - Allergies
 - Antimicrobial indication
 - Appropriate drug, dose, and duration
 - Culture review for deescalation or drug bug mismatch
 - Discontinuation

- Pharmacy Services
 - Emergency Department culture/sensitivity review
 - IV to PO
 - Renal adjustments
 - Dosing and monitoring
 - Vancomycin

Get Better Here.

- Pip/tazo
- Aminoglycosides
- Penicillin allergy testing



Stewardship Tracking

Daily

- De-escalation
- Discontinuation
- Dose Optimization
- Formulary Substitution
- Renal Adjustment
- Culture/ Sensitivity Review
- New Drug
- Information Provided
- IV to PO
- Level Ordered
- Contraindication
- Discharge Intervention

- Monthly
 - Percentage of accepted recommendations
 - Total interventions
- Quarterly
 - Days of Therapy (DOT)
 - Acquisition cost
 - Highest cost antimicrobials
- Yearly
 - Acquisition cost
 - Drug resistance
 - Antibiogram



Stewardship Focus

- Sepsis core measures
- Asymptomatic bacteriuria
- Allergy reporting
- Transitions of care



Sepsis

- Pharmacist carries sepsis pager 7a-11p
 Alerted if lactate >2.0
- Sepsis bundle "cheat sheets" at all workstations
- Pharmacist worklist
- Achieving compliance
 - Emergency department education
 - Role of ED Pharmacist
 - Automatic lactate rule



Core Measure

Southwest General Get Better Here.

<u>SEVERE SEPSIS</u> Core Measure Definition $(A + B + C)^{1,2}$

A + B + C within 6 hours of each other meets Severe Sepsis definition		
Α.	B. Any two (2)	C. ANY one (1)
Source of Infection	SIRS criteria	Organ dysfunction
Documentation of infection or possible infection by provider with date/time	Temp > 38.3 or < 36	Acute Respiratory Failure:
		new requirement for
		invasive or noninvasive
		mechanical ventilation
		SBP < 90 or MAP < 65 or
	HR > 95	SBP drop by >40 points
		from normal
	RR > 22	Creatinine > 2 or UO
		< 0.5 kg/hr x 2 hrs
		Bilirubin > 2
	WBC > 12 or < 4	Platelet count < 100,000
	or 10% bands	INR > 1.5 or PTT > 60
		Lactate > 2

SEPTIC SHOCK Core Measure Definition (A or B)^{1,2}

A or B meets Septic Shock definition		
Α.	В.	
Lactate level > 4	Identification of severe sepsis (as above) AND	
(automatically treat as shock)	Tissue hypoperfusion within the 1st hour after fluids infused: readings meeting BP criteria defined under C above	

Partnering with University Hospitals

3 HOUR BUNDLE

- 1. Measure lactate level
- Obtain blood cultures prior to administration of antibiotics
- 3. Administer broad spectrum antibiotics
- 4. Administer crystalloid fluids at 30 ml/kg

6 HOUR BUNDLE

- 1. Repeat initial lactate if level >2
- 2. Vasopressor initiated if unresponsive to fluids
- Focused exam documented by provider after fluids started
 - a. Vitals
 - b. Cardiopulmonary evaluation
 - c. Capillary refill examination
 - d. Peripheral pulse evaluation
 - e. Skin examination

Antibiotic Therapy

SEVERE SEPSIS ANTIBIOTIC THERAPY^{1,2}

Within 3 hours of diagnosis of Severe Sepsis, MUST HAVE 1 MONOTHERAPY OR 2 COMBINATION THERAPY (1 from Column A + 1 from Column B)

MONOTHERAPY	COMBINATION THERAPY	
	Column A	Column B
Amoxicillin/clauvulanate	Amikacin	Cefazolin
Ampicillin/sulbactam	Gentamicin	Clindamycin IV
Piperacillin/tazobactam	Tobramycin	Vancomycin IV
Ceftriaxone	Aztreonam	Linezolid ^{ID CONSULT}
Cefepime	Ciprofloxacin	Daptomycin ^{ID CONSULT}
Meropenem ^{ID CONSULT}		Azithromycin
Levofloxacin		Penicillins (Ampicillin, Nafcillin, Oxacillin, PCN G)

For antibiotics specific to source of infection, refer to Sepsis Order Set

INFECTION	GUIDED ANTIBIOTIC THERAPY		
INFECTION	NKDA	PCN Allergy	
Abdominal	→Zosyn 3.375 g IV Q6H	→Ceftriaxone 1 g IV Q24H + Metronidazole 500 mg IV Q8H	
Pyelonephritis	→Zosyn 3.375 g IV Q6H	→Cefepime 1 g IV Q8H	
Localized SSTI**	→Unasyn 3g IV Q6H +/-Vancomycin 15 mg/kg IV Q12	→Ceftriaxone 1 g IV Q24H +/- Vancomycin 15 mg/kg IV Q12	
Necrotizing SSTI**	→Zosyn 3.375 g IV Q6H + Vancomycin 15 mg/kg IV Q12	→Meropenem 1 g IV Q8 +Vancomycin 15 mg/kg IV Q12	
	+Clindamycin 900 mg IV Q8H	+Clindamycin 900 mg IV Q8H	
Neutropenic	→Cefepime 1 g IV Q8H + Vancomycin 15 mg/kg IV Q12		
Respiratory/CAP*	→Ceftriaxone 1 g IV Q24H +Azithromycin 500 mg IV Q24	→ Levofloxacin 750 mg IV Q24	
	+/- Vancomycin 15 mg/kg IV Q12	+/- Vancomycin 15 mg/kg IV Q12	
Respiratory/HCAP/HAP*	→ Zosyn 3.375 g IV Q6H + Levofloxacin 750 mg IV Q24	→Cefepime 1 g Q8H + Levofloxacin 750 mg IV Q24	
	+/- Vancomycin 15 mg/kg IV Q12	+/- Vancomycin 15 mg/kg IV Q12	
Unknown Source	→Vancomycin 15 mg/kg IV Q12 + Zosyn 3.375 g IV Q6H		
LODE OPECIEIC OPPERATE FOR CU	IDED THERAPY **_SVIN AND SOLET TISSUE INEECTION		



Asymptomatic Bacteriuria

Population	Prevalence, %	
Healthy, premenopausal women	1-5%	
Pregnant women	1.9-9.5%	
Postmenopausal women aged 50-70	2.8-8.6%	
Diabetic patients (Women, Men)	9-27%, 0.7-11%	
Elderly person in the community (<u>></u> 70 years) (Women, Men)	10.8-16%, 3.6-19%	
Elderly person in long term care facility (>70 years) (Women, Men)	25-50%. 15-40%	
Patient with spinal cord injuries		
Intermittent catheter use	23-89%	
Sphincterotomy and condom catheter in place	57%	
Hemodialysis	28%	
Indwelling catheter use		
Short term	9-23%	
Long term	100%	

Clin Infect Dis (2005) 40, 643-54

Southwest General Get Better Here.

Asymptomatic Bacteriuria, cont'd

- Identify the problem
 - Data collection
- Develop a solution
 - Education
 - Algorithm to assist clinical decision making
 - Ordering urine cultures
- Pushback
 - Change in mental status
 - Family pressure



Allergy Testing

- Program developed June 2016 after PGY-1 resident identified area of need
- ID consult needed to allow for appropriate chart review
 - 59% of patients missing reaction
 - Student utilization
- Pushback
 - Time commitment
 - Pharmacists cannot administer testing



Transitions of Care

Get Better Here.

- Program developed by PGY-2 Ambulatory Care resident
- Daily communication with ECF
- Identify potential discharges with antimicrobial therapy
 - Duration of antibiotics
 - Stop date
 - IV to PO opportunities
 - Laboratory Monitoring
 - De-escalation opportunities



Standard MM.09.01

Element of Performance	Plan
EP 2: Physician Education	 Quality dashboard available on intranet Yearly presentation to all departments Antibiogram distribution annually at Medical Staff Computer based learning on program highlights
EP 3: Patient Education	 Admission binder with educational materials from CDC for all patients Educational material on discharge for patients treated with antimicrobials
EP 5: CDC Core Elements	• Action: indication is specified in chart, 48 hour phone calls to assess therapy, antibiotics time out at 5 days



Program Outcomes

Antimicrobial Cost per Year





Program Outcomes-Costs

Cost per Patient per Day Adjusted for 1000 Patient Days





Program Outcomes, C-Diff

C-Difficile (Hospital Acquired)

1.6 1.4 1.2 1 0.8 0.6 0.4 0.2 0 1 st Qtr 2nd Qtr 3rd Qtr 4th Qtr = 2015 = 2016

2015: N=42 2016: N=23

2015: N=82 2016: N=37



C-Difficile (Community Acquired)

Program Outcomes-Antibiotics

Antibiotic	DOT per 1000 pt days before ASP (2014)	DOT per 1000 pt days after ASP (2016)
Meropenem	19.2	11.3
Ertapenem	3.8	3.3
Daptomycin	1.9	1.1
Linezolid	6.0	3.7
Tigecycline	0.6	0.3
Micafungin	1.0	1.5
Ceftaroline	5.5	0
Aztreonam	3.0	0.4
Pip/tazo	71.3	78.6
Vancomycin IV	99.4	100.4



Effective Practices

- Antimicrobial Stewardship Guide
- Daily face-to-face interaction
- Education
- Automatic stop orders
- Strict 24 hour restricted antibiotic policy
- Allergy clarification
- Utilize students
- Program growth



Lessons Learned

- ASP members have multiple roles in a community hospital
- Continuous surveillance lacking
- No formal mechanism of data collection or clinical support technology
- Contacting private practice practitioners
- Practitioners may be hesitant to adopt new practices



Key Concepts

- Pharmacist driven stewardship efforts can be effective and successful
- Education to practitioners is vital for program success
- Stay visible on floors
- Utilize stewardship team and resources
- Be persistent but don't jeopardize physician autonomy



Next Steps

- Continued education to staff
- Identified areas for improvement
 - Antimicrobial use in respiratory infections
 - Antimicrobial use in abdominal infections
 - Discharge prescriptions
 - NHSN reporting
 - Reduction of PPIs



Southwest General Stewardship Team

- David Blossom, MD
- Rebecca Margevicius, PharmD, BCPS
- Karen Shrimpton, BS MT(ACSP)
- Colleen Gazzillo, RN
- Sue Markland, RN
- Sandra Chisar, MD



Contact Information

February 14, 2017

Rebecca Margevicius, Pharm.D., BCPS Clinical Pharmacy Specialist Antimicrobial Stewardship rmargevicius@swgeneral.com



References

- Fridkin SK, Baggs J, Fagan R, et al. Vital Signs: Improving Antibiotic Use Among Hospitalized Patients. *MMWR. Morbidity and mortality weekly report.* 2014;63.
- Nadine Shehab, Priti R. Patel, Arjun Srinivasan, Daniel S. Budnitz; Emergency Department Visits for Antibiotic-Associated Adverse Events. *Clin Infect Dis* 2008; 47 (6): 735-743. doi: 10.1086/591126
- Centers for Disease Control and Prevention. Outpatient antibiotic prescriptions – United States, 2014. Available via the internet https://www.cdc.gov/getsmart/community/pdfs/annualreportsummary_2014.pdf
- Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults.[erratum appears in Clin Infect Dis. 2005 May 15;40(10):1556], Clin Infect Dis, 2005, vol. 40 (pg. 643-54)

